{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:14Z","timestamp":1793747054428,"version":"4.6.1"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014538","name":"Lembaga Pengelola Dana Pendidikan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019899","name":"Kementerian Keuangan Republik Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","award":["20230722299954"],"award-info":[{"award-number":["20230722299954"]}],"id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105012","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:01:08Z","timestamp":1762833668000},"page":"105012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-8240","authenticated-orcid":false,"given":"Muhammad","family":"Habiburrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-1383","authenticated-orcid":false,"given":"James M.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2025.105012_bib1","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/ijc.27980","article-title":"Clinicopathological and functional significance of XRCC1 expression in ovarian cancer","volume":"132","author":"Abdel-Fatah","year":"2013","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105012_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2019.10.035","article-title":"PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers","volume":"469","author":"Ali","year":"2020","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","article-title":"A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities","volume":"24","author":"Alizadeh","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105012_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s10038-020-0780-4","article-title":"Genetic and epigenetic profiling of BRCA1\/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1\/2 DNA methylation signature","volume":"65","author":"Aref-Eshghi","year":"2020","journal-title":"J. Hum. Genet."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105012_bib5","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/bioinformatics\/btx454","article-title":"Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer","volume":"33","author":"Baker","year":"2017","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105012_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052622","article-title":"TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues","volume":"22","author":"Bartha","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105012_bib7","unstructured":"Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D.W., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., Godwin, A.K., Gross, J., Hartmann, L., Huang, M., Huntsman, D.G., Iacocca, M., Imielinski, M., Kalloger, S., Karlan, B.Y., Levine, D.A., Mills, G.B., Morrison, C., Mutch, D., Olvera, N., Orsulic, S., Park, K., Petrelli, N., Rabeno, B., Rader, J.S., Sikic, B.I., Smith-McCune, K., Sood, A.K., Bowtell, D., Penny, R., Testa, J.R., Chang, K., Creighton, C.J., Dinh, H.H., Drummond, J.A., Fowler, G., Gunaratne, P., Hawes, A.C., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., Santibanez, J., Reid, J.G., Trevino, L.R., Wu, Y.Q., Wang, M., Muzny, D.M., Wheeler, D.A., Gibbs, R.A., Getz, G., Lawrence, M.S., Cibulskis, K., Sivachenko, A.Y., Sougnez, C., Voet, D., Wilkinson, J., Bloom, T., Ardlie, K., Fennell, T., Baldwin, J., Nichol, R., Fisher, S., Gabriel, S., Lander, E.S., Ding, L., Fulton, R.S., Koboldt, D.C., McLellan, M.D., Wylie, T., Walker, J., O\u2019Laughlin, M., Dooling, D.J., Fulton, L., Abbott, R., Dees, N.D., Zhang, Q., Kandoth, C., Wendl, M., Schierding, W., Shen, D., Harris, C.C., Schmidt, H., Kalicki, J., Delehaunty, K.D., Fronick, C.C., Demeter, R., Cook, L., Wallis, J.W., Lin, L., Magrini, V.J., Hodges, J.S., Eldred, J.M., Smith, S.M., Pohl, C.S., Vandin, F., Upfal, E., Raphael, B.J., Weinstock, G.M., Mardis, E.R., Wilson, R.K., Meyerson, M., Winckler, W., Getz, G., Verhaak, R.G.W., Carter, S.L., Mermel, C.H., Saksena, G., Nguyen, H., Onofrio, R.C., Lawrence, M.S., Hubbard, D., Gupta, S., Crenshaw, A., Ramos, A.H., Ardlie, K., Chin, L., Protopopov, A., Zhang, J., Kim, T.M., Perna, I., Xiao, Y., Zhang, H., Ren, G., Sathiamoorthy, N., Park, R.W., Lee, E., Park, P.J., Kucherlapati, R., Absher, D.M., Waite, L., Sherlock, G., Brooks, J.D., Li, J.Z., Xu, J., Myers, R.M., Laird, P.W., Cope, L., Herman, J.G., Shen, H., Weisenberger, D.J., Noushmehr, H., Pan, F., Triche Jr, T., Berman, B.P., Van Den Berg, D.J., Buckley, J., Baylin, S.B., Spellman, P.T., Purdom, E., Neuvial, P., Bengtsson, H., Jakkula, L.R., Durinck, S., Han, J., Dorton, S., Marr, H., Choi, Y.G., Wang, V., Wang, N.J., Ngai, J., Conboy, J.G., Parvin, B., Feiler, H.S., Speed, T.P., Gray, J.W., Levine, D.A., Socci, N.D., Liang, Y., Taylor, B.S., Schultz, N., Borsu, L., Lash, A.E., Brennan, C., Viale, A., Sander, C., Ladanyi, M., Hoadley, K.A., Meng, S., Du, Y., Shi, Y., Li, L., Turman, Y.J., Zang, D., Helms, E.B., Balu, S., Zhou, X., Wu, J., Topal, M.D., Hayes, D.N., Perou, C.M., Getz, G., Voet, D., Saksena, G., Zhang, J., Zhang, H., Wu, C.J., Shukla, S., Cibulskis, K., Lawrence, M.S., Sivachenko, A., Jing, R., Park, R.W., Liu, Y., Park, P.J., Noble, M., Chin, L., Carter, H., Kim, D., Samayoa, J., Karchin, R., Spellman, P.T., Purdom, E., Neuvial, P., Bengtsson, H., Durinck, S., Han, J., Korkola, J.E., Heiser, L.M., Cho, R.J., Hu, Z., Parvin, B., Speed, T.P., Gray, J.W., Schultz, N., Cerami, E., Taylor, B.S., Olshen, A., Reva, B., Antipin, Y., Shen, R., Mankoo, P., Sheridan, R., Ciriello, G., Chang, W.K., Bernanke, J.A., Borsu, L., Levine, D.A., Ladanyi, M., Sander, C., Haussler, D., Benz, C.C., Stuart, J.M., Benz, S.C., Sanborn, J.Z., Vaske, C.J., Zhu, J., Szeto, C., Scott, G.K., Yau, C., Hoadley, K.A., Du, Y., Balu, S., Hayes, D.N., Perou, C.M., Wilkerson, M.D., Zhang, N., Akbani, R., Baggerly, K.A., Yung, W.K., Mills, G.B., Weinstein, J.N., Penny, R., Shelton, T., Grimm, D., Hatfield, M., Morris, S., Yena, P., Rhodes, P., Sherman, M., Paulauskis, J., Millis, S., Kahn, A., Greene, J.M., The Cancer Genome Atlas Research, N., Disease working, g., tissue source, s., Genome sequencing centres: Baylor College of, M., Broad, I., Washington University in St, L., Cancer genome characterization centres: Broad Institute\/Dana-Farber Cancer, I., Harvard Medical, S., HudsonAlpha Institute\/Stanford, U., University of Southern California\/Johns Hopkins, U., Lawrence Berkeley National, L., Memorial Sloan-Kettering Cancer, C., University of North Carolina at Chapel, H., Genome data analysis centres: Broad, I., Johns Hopkins, U., University of California Santa Cruz\/Buck, I., The University of Texas, M.D.A.C.C., Biospecimen core, r., Data coordination, c., 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615."},{"key":"10.1016\/j.critrevonc.2025.105012_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2407-13-90","article-title":"Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer","volume":"13","author":"Bi","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/mc.23610","article-title":"Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma","volume":"62","author":"Bitler","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","article-title":"MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer","volume":"13","author":"Bustos","year":"2023","journal-title":"Cell Biosci."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105012_bib12","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.4161\/cc.25795","article-title":"Polycomb repressive complex 2 contributes to DNA double-strand break repair","volume":"12","author":"Campbell","year":"2013","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3324\/haematol.2019.240713","article-title":"Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma","volume":"106","author":"Caracciolo","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.105012_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression omnibus database","volume":"1418","author":"Clough","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"10106","key":"10.1016\/j.critrevonc.2025.105012_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105012_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030110","article-title":"DNA damage, homology-directed repair, and DNA methylation","volume":"3","author":"Cuozzo","year":"2007","journal-title":"PLOS Genet."},{"issue":"32","key":"10.1016\/j.critrevonc.2025.105012_bib18","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040829","article-title":"Exploring the role of mutations in fanconi anemia genes in hereditary cancer patients","volume":"12","author":"Del Valle","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7413","key":"10.1016\/j.critrevonc.2025.105012_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nature11333","article-title":"Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2","volume":"488","author":"Doege","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/djq509","article-title":"Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2","volume":"103","author":"Drew","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.yexmp.2014.09.019","article-title":"Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization","volume":"97","author":"Fermento","year":"2014","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105012_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.20517\/cdr.2022.13","article-title":"Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer","author":"Flynn","year":"2022","journal-title":"Cancer Drug Resist 5(2"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-12-0514","article-title":"Mechanisms of resistance to PARP inhibitors--three and counting","volume":"3","author":"Fojo","year":"2013","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib26","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/0008-5472.CAN-18-3592","article-title":"N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance","volume":"79","author":"Fukumoto","year":"2019","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105012_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jmoldx.2018.10.007","article-title":"Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing","volume":"21","author":"Grimm","year":"2019","journal-title":"J. Mol. Diagn."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jmoldx.2018.10.007","article-title":"Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing","volume":"21","author":"Grimm","year":"2019","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib30","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","volume":"45","author":"Gy\u0151rffy","year":"2023","journal-title":"Geroscience"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib31","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gy\u0151rffy","year":"2024","journal-title":"Innovation"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2024.2357518","article-title":"Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells","volume":"19","author":"He","year":"2024","journal-title":"Epigenetics"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105012_bib33","article-title":"Promoter Methylation Changes in DNA Damage-Response Genes in Ovarian Cancer and Their Correlation with Prognosis","volume":"51","author":"He","year":"2024","journal-title":"CEOG"},{"key":"10.1016\/j.critrevonc.2025.105012_bib34","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105012_bib36","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.7150\/jca.56135","article-title":"CREBBP knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer","volume":"12","author":"Hu","year":"2021","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab028","article-title":"Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance","volume":"3","author":"Hurley","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.critrevonc.2025.105012_bib38","unstructured":"IARC, 2023. Globocan 2022; World. \u3008https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf\u3009. (Accessed 30 October 2023)."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105012_bib39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/2767-9764.CRC-22-0119","article-title":"Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition","volume":"2","author":"Jamal","year":"2022","journal-title":"Cancer Res Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib40","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","article-title":"PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends Mol. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib41","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3892\/mmr.2015.3580","article-title":"Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma","volume":"12","author":"Jiang","year":"2015","journal-title":"Mol. Med Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","article-title":"PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance","volume":"51","author":"Kanev","year":"2024","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41467-018-03031-3","article-title":"CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity","volume":"9","author":"Karakashev","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105012_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3892\/br.2017.990","article-title":"Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer (Review)","volume":"7","author":"Kawahara","year":"2017","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.critrevonc.2025.105012_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021263","article-title":"Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets","author":"Khamidullina","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"645","key":"10.1016\/j.critrevonc.2025.105012_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aba8091","article-title":"Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability","volume":"13","author":"Kharat","year":"2020","journal-title":"Sci. Signal"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105012_bib47","article-title":"Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients","volume":"15","author":"Kirmizitas","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105012_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.974885","article-title":"Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF\/c-MET axis","volume":"12","author":"Klotz","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib49","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1389202923666220527114108","article-title":"Construction of PARPi Resistance-related Competing Endogenous RNA Network","volume":"23","author":"Kong","year":"2022","journal-title":"Curr. Genom."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib51","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib53","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bbrc.2019.03.155","article-title":"Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas","volume":"513","author":"Kukita","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105012_bib54","doi-asserted-by":"crossref","DOI":"10.2196\/27633","article-title":"Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J. Med Internet Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2007.03.041","article-title":"Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma","volume":"106","author":"Lee","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105012_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713454","article-title":"Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours","volume":"24","author":"Legrand","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105012_bib57","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ultrasmedbio.2020.11.001","article-title":"Ultrasound Microbubble-Mediated VHL Regulates the Biological Behavior of Ovarian Cancer Cells","volume":"47","author":"Li","year":"2021","journal-title":"Ultrasound Med. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105012_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105012_bib62","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3892\/ijmm.2014.1661","article-title":"Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1\u03b1\/miR-210\/VMP1 signaling pathway","volume":"33","author":"Liu","year":"2014","journal-title":"Int J. Mol. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib64","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/1878-0261.12909","article-title":"Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors","volume":"15","author":"Lobo","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105012_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102111","article-title":"Newly diagnosed ovarian cancer: Which first-line treatment?","volume":"91","author":"Lorusso","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.105012_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101885","article-title":"Selective modulation by PARP-1 of HIF-1\u03b1-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions","volume":"41","author":"Mart\u00ed","year":"2021","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105012_bib68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ccell.2016.03.009","article-title":"Intratumoral Heterogeneity of the Epigenome","volume":"29","author":"Mazor","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.celrep.2018.03.038","article-title":"Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas","volume":"23","author":"Meghani","year":"2018","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146256","article-title":"Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models","volume":"131","author":"Mehibel","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.105012_bib72","article-title":"A gene set enrichment analysis for the cancer hallmarks","author":"Menyhart","year":"2024","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib73","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bcp.2014.08.026","article-title":"PARP and other prospective targets for poisoning cancer cell metabolism","volume":"92","author":"Michels","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105012_bib74","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105012_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib76","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.105012_bib77","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib78","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13046-019-1245-5","article-title":"New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools","volume":"38","author":"Mu\u00f1oz-Galv\u00e1n","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105012_bib79","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","article-title":"Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma","volume":"81","author":"Nesic","year":"2021","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105012_bib80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105012_bib81","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","article-title":"A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1","volume":"73","author":"Oike","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105012_bib83","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"issue":"7553","key":"10.1016\/j.critrevonc.2025.105012_bib84","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105012_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110376","article-title":"Astragalus polysaccharides sensitize ovarian cancer stem cells to PARPi by inhibiting mitophagy via PINK1\/Parkin signaling","volume":"27","author":"Peng","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib86","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105012_bib87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gde.2019.03.001","article-title":"Dissecting PARP inhibitor resistance with functional genomics","volume":"54","author":"Pettitt","year":"2019","journal-title":"Curr. Opin. Genet Dev."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cancers15010006","article-title":"Epigenetic Insights on PARP-1 Activity in Cancer Therapy","volume":"15","author":"Pinton","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib90","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13048-020-00753-1","article-title":"Germline variation of Ribonuclease H2 genes in ovarian cancer patients","volume":"13","author":"Polaczek","year":"2020","journal-title":"J. Ovarian Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105012_bib91","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12863-021-01022-w","article-title":"Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker","volume":"23","author":"Qiu","year":"2022","journal-title":"BMC Genom. Data"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105012_bib93","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/carcin\/bgq150","article-title":"EZH2 supports ovarian carcinoma cell invasion and\/or metastasis via regulation of TGF-\u03b21 and is a predictor of outcome in ovarian carcinoma patients","volume":"31","author":"Rao","year":"2010","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib94","doi-asserted-by":"crossref","first-page":"637","DOI":"10.20517\/cdr.2021.146","article-title":"Ovarian cancer resistance to PARPi and platinum-containing chemotherapy","volume":"5","author":"Rebekah","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib95","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12885-021-08413-3","article-title":"Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma","volume":"21","author":"Reid","year":"2021","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105012_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249708","article-title":"BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor","volume":"21","author":"Sahnane","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12916-023-03075-3","article-title":"The Biomarker Toolkit - an evidence-based guideline to predict cancer biomarker success and guide development","volume":"21","author":"Savva","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.critrevonc.2025.105012_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.123.1.223","article-title":"Scatter factor\/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development","volume":"123","author":"Sonnenberg","year":"1993","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105012_bib100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","article-title":"Biomarker Assessment of HR Deficiency, Tumor BRCA1\/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy","volume":"16","author":"Stronach","year":"2018","journal-title":"Mol. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib101","doi-asserted-by":"crossref","first-page":"637","DOI":"10.20517\/cdr.2021.146","article-title":"Ovarian cancer resistance to PARPi and platinum-containing chemotherapy","volume":"5","author":"Summey","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105012_bib102","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/jnci\/djt302","article-title":"miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition","volume":"105","author":"Sun","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.105012_bib103","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9052","article-title":"EZH2\/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer","volume":"8","author":"Sun","year":"2020","journal-title":"PeerJ"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100987","article-title":"MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2\/\u03b2-catenin in serous ovarian cancers","volume":"14","author":"Sun","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib105","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105012_bib107","doi-asserted-by":"crossref","DOI":"10.1097\/MOU.0000000000001297","article-title":"Toxicities of PARP inhibitors in genitourinary cancers","volume":"35","author":"Szalontai","year":"2025","journal-title":"Curr. Opin. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.37349\/etat.2020.00003","article-title":"Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer","volume":"1","author":"Taylor","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"issue":"33","key":"10.1016\/j.critrevonc.2025.105012_bib109","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Tew","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7618","key":"10.1016\/j.critrevonc.2025.105012_bib110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature19081","article-title":"Tumour hypoxia causes DNA hypermethylation by reducing TET activity","volume":"537","author":"Thienpont","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib111","article-title":"Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more. BMJ","volume":"3","author":"Timoth\u00e9e","year":"2024","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13072-022-00445-8","article-title":"TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation","volume":"15","author":"Toli\u0107","year":"2022","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib113","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12916-017-0870-0","article-title":"Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer","volume":"15","author":"Tomar","year":"2017","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105012_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/genes12030446","article-title":"The PARP Way to Epigenetic Changes","volume":"12","author":"Ummarino","year":"2021","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13046-019-1490-7","article-title":"MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1","volume":"39","author":"Vescarelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105012_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111462","article-title":"PARP-inhibition reprograms macrophages toward an anti-tumor phenotype","volume":"41","author":"Wang","year":"2022","journal-title":"Cell Rep."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105012_bib117","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/0008-5472.CAN-12-0103","article-title":"MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12929-023-00909-3","article-title":"E26 transformation-specific transcription variant 5 in development and cancer: modification, regulation and function","volume":"30","author":"Wei","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2025.105012_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217192","article-title":"Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer","author":"Wu","year":"2024","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105012_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109575","article-title":"YAP\/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells","volume":"9","author":"Xia","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105012_bib122","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/febs.15636","article-title":"PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment","volume":"288","author":"Yang","year":"2021","journal-title":"Febs J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105012_bib123","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1038\/s41598-024-83977-1","article-title":"KAT2B inhibits proliferation and invasion via inactivating TGF-\u03b2\/Smad3 pathway-medicated autophagy and EMT in epithelial ovarian cancer","volume":"15","author":"Yao","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.105012_bib124","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.semcancer.2015.03.007","article-title":"Therapeutic targeting of replicative immortality","volume":"35","author":"Yaswen","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105012_bib125","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.17305\/bb.2024.11314","article-title":"The association of rs25487 of the XRCC1 gene and rs13181 of the ERCC2 gene polymorphisms with the ovarian cancer risk","volume":"25","author":"Zavarykina","year":"2024","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.critrevonc.2025.105012_bib126","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Huang, J., Wang, B., Shen, J., Long, M., Fan, Y., Montone, K.T., Tanyi, J.L., Tavana, O., Chan, H.M., Hu, X., Zhang, L., 2024. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. eLife Sciences Publications, Ltd 13, RP99225.","DOI":"10.7554\/eLife.99225.1"},{"issue":"45","key":"10.1016\/j.critrevonc.2025.105012_bib127","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012996","article-title":"XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: a systematic review and MOOSE-compliant meta-analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2025.105012_bib128","article-title":"Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:45:47Z","timestamp":1768333547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":128,"alternative-id":["S1040842825004007"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105012","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105012"}}